非侵入性肝纤维化指数与心力衰竭死亡率之间的关联
Selim Aydemir1, Sidar Şiyar Aydin2, Onur Altinkaya1
1Department of Cardiology, University of Health Sciences, Erzurum City Hospital, Erzurum, Turkey.
Medicine
|January 21, 2026
概括
非侵入性肝纤维化指数,APRI和FIB-4,预测心力衰竭 (HF) 的死亡率. 在预测所有HF类型的死亡率方面,FIB-4得分优于APRI,有助于预后.
科学领域:
- 心脏病学 心脏病学
- 肝病学 肝病学是一种肝病学.
- 医学预测 医学预测
背景情况:
- 心力衰竭 (HF) 是疾病和死亡的日益严重的原因.
- 在HF患者中的肝纤维化与不良结果相关.
- 对HF死亡率的预测工具对于患者管理至关重要.
研究的目的:
- 评估非侵入性肝纤维化指数与心力衰竭死亡率之间的关系.
- 为了比较APRI和FIB-4评分对HF死亡率的预测性表现.
主要方法:
- 对2029名高发烧患者 (2017-2024) 的回顾性分析.
- 肝纤维化指数的计算:AST/ALT比率,APRI,以及FIB-4.
- 考克斯回归和ROC曲线分析以确定死亡率预测因素.
主要成果:
- APRI和FIB-4指数独立预测HF死亡率.
- 与APRI相比,FIB-4得分显示出更好的预测能力.
- AST/ALT比率不是HF死亡率的重要预测因素.
结论:
- FIB-4和APRI是HF死亡率预测的有价值,易于计算的非侵入性标记.
- 这些指数可以帮助HF随访和预后估计.
- FIB-4与所有HF类型的死亡率有关;APRI预测HFrEF和HFmrEF的死亡率.
相关概念视频
Heart Failure II: Pathophysiology
783
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction
723
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
Heart Failure VI: Adjunct Therapies
277
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
Heart Failure Drugs: Diuretics
824
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227


